Savara Inc. operates as an orphan lung disease company. More Details
Excellent balance sheet and overvalued.
Share Price & News
How has Savara's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SVRA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: SVRA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: SVRA underperformed the US Biotechs industry which returned 23.1% over the past year.
Return vs Market: SVRA underperformed the US Market which returned 39.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Savara's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StDavid Ramsay Is The Independent Director of Savara Inc. (NASDAQ:SVRA) And They Just Picked Up 6.2% More Shares
1 month ago | Simply Wall StWhat Type Of Shareholders Make Up Savara Inc.'s (NASDAQ:SVRA) Share Registry?
7 months ago | Simply Wall StBreakeven On The Horizon For Savara Inc. (NASDAQ:SVRA)
Is Savara undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SVRA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SVRA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SVRA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: SVRA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SVRA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SVRA is good value based on its PB Ratio (1.1x) compared to the US Biotechs industry average (3.4x).
How is Savara forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SVRA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SVRA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SVRA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SVRA is forecast to have no revenue next year.
High Growth Revenue: SVRA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SVRA's Return on Equity is forecast to be high in 3 years time
How has Savara performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SVRA is currently unprofitable.
Growing Profit Margin: SVRA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SVRA is unprofitable, and losses have increased over the past 5 years at a rate of 23.1% per year.
Accelerating Growth: Unable to compare SVRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SVRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: SVRA has a negative Return on Equity (-25.36%), as it is currently unprofitable.
How is Savara's financial position?
Financial Position Analysis
Short Term Liabilities: SVRA's short term assets ($194.8M) exceed its short term liabilities ($7.2M).
Long Term Liabilities: SVRA's short term assets ($194.8M) exceed its long term liabilities ($25.3M).
Debt to Equity History and Analysis
Debt Level: SVRA's debt to equity ratio (14.4%) is considered satisfactory.
Reducing Debt: SVRA's debt to equity ratio has increased from 6.2% to 14.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SVRA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SVRA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 24.8% each year
What is Savara current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SVRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SVRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SVRA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SVRA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SVRA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Matt Pauls (49 yo)
Mr. Matthew Pauls, also known as Matt, serves as Chief Executive Officer at Savara Inc. since December 8, 2020, serves as Chairman of the Board since September 11, 2020 and serves as Member of the Board si...
CEO Compensation Analysis
Compensation vs Market: Matt's total compensation ($USD2.32M) is above average for companies of similar size in the US market ($USD1.06M).
Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.
Experienced Management: SVRA's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Experienced Board: SVRA's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SVRA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 117.8%.
Savara Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Savara Inc.
- Ticker: SVRA
- Exchange: NasdaqGS
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$201.149m
- Shares outstanding: 113.64m
- Website: https://www.savarapharma.com
Number of Employees
- Savara Inc.
- Building III
- Suite 200
- United States
Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/19 07:14|
|End of Day Share Price||2021/06/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.